NCCN guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma

FDA approves Adcetris + lenalidomide + rituximab for r/r large B-cell lymphoma

FDA approved Adcetris (brentuximab vedotin) in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or CAR T-cell therapy.

February 14, 2025

Vol.51 No.06

Guest Editorial

World Cancer Day 2025: A symbol of personal and collective uncertainty

My entire life I was told to respectfully question anything and everything, because questions equal answers, which provide understanding and thereby comfort—even with the uncomfortable. It’s simply in my DNA.

Chemo + immunotherapy achieve higher complete remission rates in DLBCL than either treatment alone, Mount Sinai trial finds

In a phase Ib/II clinical trial known as EPCORE NHL-2, a team of researchers—led by Joshua Brody, director of the Lymphoma Immunotherapy Program at the Tisch Cancer Institute at Mount Sinai—showed the benefit of combining chemotherapy with immunotherapy for diffuse large B-cell lymphoma. The results were published earlier this month in the journal Blood.

January 31, 2025

Vol.51 No.04

Guest Editorial

FDA and OHRP draft guidance aims to improve ethics of tissue biopsies in clinical trials

The U.S. Food and Drug Administration and the U.S. Department of Health and Human Services Office of Human Research Protections issued Draft Guidance on the inclusion of tissue biopsies in clinical trials.

January 17, 2025

Vol.51 No.02

By Laura A. Levit, Mark J. Ratain, Julie R. Gralow, Clifford A. Hudis and Elizabeth Garrett-Mayer

Clinical

NCCN publishes patient resource on genetic testing to guide patient decisionmaking

The National Comprehensive Cancer Network published its first patient resource aimed at informing people about the latest recommendations around hereditary and familial cancer risk. The document provides guidance on testing for inherited genetic mutations that can raise the risk of cancer.

Antibody shows encouraging results for treating high-risk follicular lymphoma and marginal zone lymphoma

Two clinical trials testing the antibody Zynlonta (loncastuximab tesirine) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and marginal zone lymphoma.

December 13, 2024

Vol.50 No.46

NCCN guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma

YOU MAY BE INTERESTED IN

FDA approves Adcetris + lenalidomide + rituximab for r/r large B-cell lymphoma

World Cancer Day 2025: A symbol of personal and collective uncertainty

Chemo + immunotherapy achieve higher complete remission rates in DLBCL than either treatment alone, Mount Sinai trial finds

FDA and OHRP draft guidance aims to improve ethics of tissue biopsies in clinical trials

NCCN publishes patient resource on genetic testing to guide patient decisionmaking

Antibody shows encouraging results for treating high-risk follicular lymphoma and marginal zone lymphoma

Renew today!

Subscriber content

Never miss an issue!

Login